HC Wainwright Estimates Replimune Group Q3 Earnings

Replimune Group, Inc. (NASDAQ:REPL) – HC Wainwright issued their Q3 2026 earnings per share (EPS) estimates for Replimune Group in a report released on Friday, May 23rd. HC Wainwright analyst R. Burns anticipates that the company will post earnings of ($0.66) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $22.00 price target on the stock. The consensus estimate for Replimune Group’s current full-year earnings is ($2.97) per share. HC Wainwright also issued estimates for Replimune Group’s Q4 2026 earnings at ($0.56) EPS and FY2026 earnings at ($2.89) EPS.

Separately, JPMorgan Chase & Co. boosted their target price on shares of Replimune Group from $16.00 to $18.00 and gave the stock an “overweight” rating in a report on Wednesday, February 26th. Seven investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, Replimune Group currently has an average rating of “Buy” and a consensus price target of $19.43.

Replimune Group Stock Performance

REPL stock opened at $8.35 on Monday. The company has a market capitalization of $643.08 million, a P/E ratio of -2.72 and a beta of 0.68. The company has a debt-to-equity ratio of 0.14, a current ratio of 11.43 and a quick ratio of 11.43. The business has a 50-day moving average price of $8.63 and a 200 day moving average price of $11.20. Replimune Group has a 1-year low of $4.92 and a 1-year high of $17.00.

Replimune Group (NASDAQ:REPL) last released its quarterly earnings data on Thursday, May 22nd. The company reported ($0.82) earnings per share for the quarter, missing the consensus estimate of ($0.75) by ($0.07). During the same quarter in the previous year, the company posted ($0.25) earnings per share.

Hedge Funds Weigh In On Replimune Group

Several hedge funds have recently modified their holdings of REPL. Sterling Capital Management LLC increased its holdings in shares of Replimune Group by 364.5% during the fourth quarter. Sterling Capital Management LLC now owns 2,109 shares of the company’s stock valued at $26,000 after acquiring an additional 1,655 shares in the last quarter. US Bancorp DE boosted its position in Replimune Group by 582.6% in the first quarter. US Bancorp DE now owns 4,594 shares of the company’s stock valued at $45,000 after buying an additional 3,921 shares during the last quarter. Tower Research Capital LLC TRC boosted its position in Replimune Group by 696.7% in the fourth quarter. Tower Research Capital LLC TRC now owns 6,772 shares of the company’s stock valued at $82,000 after buying an additional 5,922 shares during the last quarter. Aster Capital Management DIFC Ltd boosted its position in Replimune Group by 8,798.9% in the fourth quarter. Aster Capital Management DIFC Ltd now owns 8,276 shares of the company’s stock valued at $100,000 after buying an additional 8,183 shares during the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank boosted its position in Replimune Group by 106.2% in the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 11,410 shares of the company’s stock valued at $111,000 after buying an additional 5,876 shares during the last quarter. Institutional investors and hedge funds own 92.53% of the company’s stock.

Insiders Place Their Bets

In other news, CAO Andrew Schwendenman sold 3,287 shares of the company’s stock in a transaction dated Tuesday, May 20th. The shares were sold at an average price of $8.05, for a total transaction of $26,460.35. Following the transaction, the chief accounting officer now owns 68,284 shares in the company, valued at $549,686.20. This represents a 4.59% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Konstantinos Xynos sold 7,952 shares of the company’s stock in a transaction dated Tuesday, May 20th. The shares were sold at an average price of $8.06, for a total transaction of $64,093.12. Following the transaction, the insider now owns 146,933 shares in the company, valued at approximately $1,184,279.98. This trade represents a 5.13% decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 74,907 shares of company stock worth $603,655. 8.80% of the stock is owned by corporate insiders.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.